These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15011325)

  • 1. [Prognosis in Alzheimer's disease].
    Kitamura S
    Nihon Rinsho; 2004 Jan; 62 Suppl():81-5. PubMed ID: 15011325
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug treatment for Alzheimer's disease.
    Tom T; Cummings JL
    West J Med; 1998 Apr; 168(4):264. PubMed ID: 9584667
    [No Abstract]   [Full Text] [Related]  

  • 3. Alzheimer's disease management.
    Cummings JL
    J Clin Psychiatry; 1998; 59 Suppl 13():4-5. PubMed ID: 9771824
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.
    Wattmo C; Wallin AK; Londos E; Minthon L
    Gerontologist; 2011 Feb; 51(1):17-27. PubMed ID: 20562471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Memantine brakes Alzheimer's dementia. The NMDA antagonist is effective in severe cases, too].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():21. PubMed ID: 14579479
    [No Abstract]   [Full Text] [Related]  

  • 6. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.
    Fillit H; Cummings J
    Manag Care Interface; 2000 Jan; 13(1):51-6. PubMed ID: 10747691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticholinesterases in the treatment of Alzheimer's dementia--the first year's experience in Argyll & Clyde.
    Hughes A; Coulter F; Gillespie R; Livingston H; Phillips K; Quinn E; Rimmer E; Smith M; Walker A
    Health Bull (Edinb); 2000 Jan; 58(1):20-4. PubMed ID: 12813848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's drug delays move to nursing home.
    Health News; 2003 Nov; 9(11):7. PubMed ID: 14619814
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic standards in Alzheimer disease.
    Doody RS
    Alzheimer Dis Assoc Disord; 1999 Nov; 13 Suppl 2():S20-6. PubMed ID: 10622675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measures to prevent Alzheimer's patients from discontinuing the use of cholinesterase inhibitors.
    Meguro K
    Psychogeriatrics; 2014 Sep; 14(3):210-1. PubMed ID: 25219960
    [No Abstract]   [Full Text] [Related]  

  • 12. New drug available for Alzheimer's disease.
    Bailey C
    Colo Nurse; 1997 Mar; 97(1):12. PubMed ID: 9095790
    [No Abstract]   [Full Text] [Related]  

  • 13. Donepezil (Aricept) therapy for Alzheimer's disease.
    Geldmacher DS
    Compr Ther; 1997 Jul; 23(7):492-3. PubMed ID: 9262925
    [No Abstract]   [Full Text] [Related]  

  • 14. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common Alzheimer's drug flunks test of effectiveness. Initial improvements in cognitive ability made by cholinesterase inhibitors soon disappear.
    Health News; 2004 Oct; 10(10):11. PubMed ID: 15584119
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in the treatment of Alzheimer's disease.
    Schneider LS
    Aging (Milano); 1998 Apr; 10(2):156-7. PubMed ID: 9666210
    [No Abstract]   [Full Text] [Related]  

  • 17. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
    Hatoum HT; Thomas SK; Lin SJ; Lane R; Bullock R
    J Med Econ; 2009 Jun; 12(2):98-103. PubMed ID: 19492974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility.
    Tariot PN; Jakimovich L
    J Am Med Dir Assoc; 2003; 4(4):216-9. PubMed ID: 12837144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    Peskind ER
    J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil and Alzheimer's dementia.
    Earl-Slater A; Walley T
    Clin Perform Qual Health Care; 2000; 8(1):47-51. PubMed ID: 11183967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.